205. 脆弱X症候群関連疾患 Disease details / Clinical trials / Drug dev / DR info


臨床試験数 : 5 / 薬物数 : 11 - (DrugBank : 7) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 31

薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
Allopregnanolone
   Randi J. Hagerman, MD
      2015   Phase 2   NCT02603926   United States
Citocoline
   Rush University Medical Center
      2015   Phase 2   NCT02197104   United States
Clinical observation
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Corticotropin-releasing hormone
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Cyclophosphamide
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Laboratory biomarker analysis
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Magnetic resonance imaging
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Memantine
   University of California, Davis
      2007   -   NCT00584948   United States
Prednisone
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States
Sulforaphane
   University of California, Davis
      2021   -   NCT05233579   United States
Therapeutic immune globulin
   Children's Oncology Group
      2004   Phase 3   NCT00033293   Australia;Canada;Netherlands;New Zealand;Puerto Rico;Switzerland;United States